New Data at ECTRIMS Highlight Positive Benefit-Risk Profile of Mavenclad in Relapsing Multiple Sclerosis
- Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo; - Analysis of 10,000 patient years of safety data provides further characterization of safety profile; - Further data suggests the relative selectivity of Mavenclad for the adaptive immune system.
- 26.10.2017, 14:51
- Kategoria: Biznes i finanse
- Źródło: PR Newswire